Salem Ajib

Dr. Senckenberg Institute Of Neurooncology
Frankfurt Am Main, HE, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Spinal cord disease following CAR T-cell therapy with axicabtagene ciloleucel in a patient with high-grade B-cell lymphoma.

Spinal cord disease following CAR T-cell therapy with axicabtagene ciloleucel in a patient with high-grade B-cell lymphoma.

Journal: Leukemia & lymphoma

Published: March 22, 2026

Central nervous system relapse after allogeneic HCT in FLT3-mutated AML.

Central nervous system relapse after allogeneic HCT in FLT3-mutated AML.

Journal: Annals of hematology

Published: August 21, 2024

Allogeneic hematopoietic cell transplantation after infection with SARS-CoV-2 during the COVID-19 pandemic: a multicenter retrospective analysis.

Allogeneic hematopoietic cell transplantation after infection with SARS-CoV-2 during the COVID-19 pandemic: a multicenter retrospective analysis.

Journal: Bone marrow transplantation

Published: August 04, 2024

Interventional antibiotic treatment replacing antibiotic prophylaxis during allogeneic hematopoietic stem cell transplantation is safe and leads to a reduction of antibiotic administration.

Interventional antibiotic treatment replacing antibiotic prophylaxis during allogeneic hematopoietic stem cell transplantation is safe and leads to a reduction of antibiotic administration.

Journal: Annals of hematology

Published: April 03, 2024

Management of Patients Undergoing CAR-T Cell Therapy in Germany.

Management of Patients Undergoing CAR-T Cell Therapy in Germany.

Journal: Oncology research and treatment

Published: September 07, 2023

Endothelial complications after allogeneic stem cell transplantation in patients with pretransplant resolved COVID-19.

Endothelial complications after allogeneic stem cell transplantation in patients with pretransplant resolved COVID-19.

Journal: Bone marrow transplantation

Published: February 01, 2022

SARS-CoV-2-specific T cells are generated in less than half of allogeneic HSCT recipients failing to seroconvert after COVID-19 vaccination.

SARS-CoV-2-specific T cells are generated in less than half of allogeneic HSCT recipients failing to seroconvert after COVID-19 vaccination.

Journal: European journal of immunology

Published: December 15, 2021

Correction to: Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.

Correction to: Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.

Journal: Annals of hematology

Published: June 23, 2021

Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.

Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.

Journal: Annals of hematology

Published: August 20, 2020

Erythrocyte depletion from bone marrow: performance evaluation after 50 clinical-scale depletions with Spectra Optia BMC.

Erythrocyte depletion from bone marrow: performance evaluation after 50 clinical-scale depletions with Spectra Optia BMC.

Journal: Journal of translational medicine

Published: June 05, 2017

Mismatched unrelated hematopoietic stem cell transplantation with post-transplant cyclophosphamide for high-risk acute myeloid leukemia.

Mismatched unrelated hematopoietic stem cell transplantation with post-transplant cyclophosphamide for high-risk acute myeloid leukemia.

Journal: Annals of hematology

Published: January 22, 2016

Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey.

Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey.

Journal: Leukemia

Published: July 17, 2015

Showing 1-12 of 13

Last Updated: 09/26/2026